# Freenome

Source: https://onco.cc/companies/freenome/  
OnCo record `freenome` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Freenome makes SimpleScreen CRC, the second FDA-approved blood test for colorectal cancer screening (July 2026), commercialised by Abbott.

## Summary

FDA approved SimpleScreen CRC on 24 July 2026 for average-risk adults 45+ based on PREEMPT CRC (>48,000 participants; ~80% CRC sensitivity, ~90% specificity). Freenome listed via a $330M SPAC merger (2025-26); Abbott holds US commercial rights and paid a $100M approval milestone; launch expected autumn 2026.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: South San Francisco, CA
- Type: diagnostics
- Website: https://www.freenome.com
- Ticker: FRNM

## Sources

- FDA approval (MedTech Dive): https://www.medtechdive.com/news/freenome-secures-fda-nod-for-blood-based-colorectal-cancer-test/826290/

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [DNA methylation profiling](https://onco.cc/technologies/methylation-profiling/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [Shield](https://onco.cc/drugs/shield/), [SimpleScreen CRC](https://onco.cc/drugs/simplescreen-crc/)
- bottlenecks: [The hardest cancers are found late](https://onco.cc/bottlenecks/b-early-detection/)
- ideas: [Offer the blood test for bowel cancer only to people who refuse stool tests or colonoscopy](https://onco.cc/ideas/idea-prev-blood-crc-test-for-non-responders/)
- roadmaps: [ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment](https://onco.cc/roadmaps/ctdna-tests/)
- companies: [Abbott Laboratories](https://onco.cc/companies/abbott/), [GV (Google Ventures)](https://onco.cc/companies/gv/), [Polaris Partners](https://onco.cc/companies/polaris-partners/)
- trials: [PREEMPT CRC](https://onco.cc/trials/preempt-crc/)
- key papers: [Clinical validation of a circulating tumor DNA-based blood test to screen for colorectal cancer (PREEMPT CRC)](https://onco.cc/key-papers/paper-preempt-crc-shaukat-jama-2025/)

---
JSON: https://onco.cc/api/v1/entities/freenome.json